Arthritis News and Research

Latest Arthritis News and Research

Most autoimmune diseases associated with increased risk of blood clots on the lung

Autoimmune diseases, in which the immune system attacks the body, are fairly common. Thyroid diseases, type 1 diabetes, rheumatoid arthritis, psoriasis and inflammatory bowel disease are some examples. Autoimmune diseases are associated with increased inflammation in the tissue, which in some cases is linked to an increased propensity to develop clots in the veins.

29 Nov 2011

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

28 Nov 2011

BUSM professor receives 2011 ACN Communication Media Award

Michael F. Holick, PhD, MD, director of the General Clinical Research Unit and professor of medicine, physiology and biophysics at Boston University School of Medicine (BUSM) was selected by the American College of Nutrition (ACN) Awards Committee as the 2011 recipient of the ACN Communication Media Award.

23 Nov 2011

CIC microGUNE and Biodonostia test a new technique for evaluating intestinal diseases in patients

The CIC microGUNE research centre and the Biodonostia Institute have recently started testing a new technique for assessing the severity of inflammatory intestinal diseases, such as Crohn's Disease, in patients at the Donostia Hospital.

23 Nov 2011

FDA accepts Regeneron's ARCALYST sBLA for review

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.

22 Nov 2011

Merck agrees to pay $950 million in Vioxx safety probe

Merck & Co. will pay $950 million and one of its units will plead guilty to a criminal charge to resolve a U.S. probe of its illegal marketing of the painkiller Vioxx.

22 Nov 2011

Post-surgery death risk high among thinner people: Study

A new study has found that thinner people are at a higher risk of dying within 30 days of an operation than heavier people. The cause behind this trend is not clear.

22 Nov 2011

Cognitive-behavioral therapy safe and effective for juvenile fibromyalgia

A recent trial shows cognitive-behavioral therapy (CBT) reduces functional disability and depressive symptoms in adolescents with juvenile fibromyalgia. The psychological intervention was found to be safe and effective, and proved to be superior to disease management education.

22 Nov 2011

Titanium particles from artificial joints may play a direct role in painful inflammation

Many people with painful, creaky knees and hips find relief after replacing their bad joints with new artificial joints made from titanium. But some of these people develop painful inflammation that can lead to bone destruction and loosening of the new joint. A new study led by researchers at the University of Medicine and Dentistry of New Jersey and published by the Journal of Immunology suggests that tiny titanium particles that flake away from the artificial joints through normal wear and tear may play a direct role in that inflammation.

22 Nov 2011

New insights into immune-system changes that may trigger cartilage breakdown

Challenging long-held notions that osteoarthritis is a result mainly of wear and tear on the joints, researchers led by Dr. William H. Robinson of the Department of Veterans Affairs Palo Alto Health Care System and Stanford University have provided new insights into the immune-system changes that may trigger cartilage breakdown.

21 Nov 2011

EMA validates Pfizer's Market Authorisation Application for tofacitinib to treat rheumatoid arthritis

Pfizer Inc. announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by the European Medicines Agency (EMA).

21 Nov 2011

Omega-3 linked with reduced joint pain and cognitive side effects of breast cancer therapy

"I know I need this medicine to help lower my chance of cancer recurrence, but it makes my joints ache and stiff. It makes me feel old and I am not sure I can take this medication much longer."

19 Nov 2011

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.

19 Nov 2011

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

An anti-malaria drug used for more than 60 years is now being studied for use in breast cancer patients whose disease has not responded to traditional chemotherapy treatment.

18 Nov 2011

ACR special issue focuses on assessing adult pain

Assessment of patient outcomes allows physicians and researchers to measure the success or failure of diagnostics and treatments that patients receive. One set of measurement tools focuses on assessing adult pain and is included in a special issue of Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), providing physicians and researchers with a single resource of 250 patient outcomes measurements in rheumatology.

17 Nov 2011

Psoriasis may alter cholesterol composition and decrease HDL function

Collaborative research from Perelman School of Medicine at the University of Pennsylvania has shown that psoriasis patients have an increased risk of heart attack, stroke and cardiovascular death, especially if the psoriasis is moderate to severe. Now, Penn researchers have discovered the potential underlying mechanism by which the inflammatory skin disease impacts cardiovascular health.

17 Nov 2011

TNF inhibitors may minimally increase risk of serious infections

Biologic drugs have revolutionized treatment of autoimmune diseases during the past decade despite belief there is an increased risk for serious infections from using them. But new research from the University of Alabama at Birmingham Center for Education and Research on Therapeutics reveals that a class of biologics called tumor necrosis factor antagonists, or TNF inhibitors, may only minimally increase risk compared to more traditional therapies.

17 Nov 2011

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.

16 Nov 2011

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Amgen announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic castration-resistant prostate cancer.

16 Nov 2011

Study identifies demographic and health related characteristics related to mobility limitation

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health and featured in a 2011 issue of the Journal of Gerontology, has identified demographic and health related characteristics that were related to mobility limitation.

15 Nov 2011

Arthritis News and Research

Latest Arthritis News and Research

Most autoimmune diseases associated with increased risk of blood clots on the lung

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

BUSM professor receives 2011 ACN Communication Media Award

CIC microGUNE and Biodonostia test a new technique for evaluating intestinal diseases in patients

FDA accepts Regeneron's ARCALYST sBLA for review

Merck agrees to pay $950 million in Vioxx safety probe

Post-surgery death risk high among thinner people: Study

Cognitive-behavioral therapy safe and effective for juvenile fibromyalgia

Titanium particles from artificial joints may play a direct role in painful inflammation

New insights into immune-system changes that may trigger cartilage breakdown

EMA validates Pfizer's Market Authorisation Application for tofacitinib to treat rheumatoid arthritis

Omega-3 linked with reduced joint pain and cognitive side effects of breast cancer therapy

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

ACR special issue focuses on assessing adult pain

Psoriasis may alter cholesterol composition and decrease HDL function

TNF inhibitors may minimally increase risk of serious infections

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Study identifies demographic and health related characteristics related to mobility limitation

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Arthritis News and Research

Latest Arthritis News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in